Semaglutide Reduces Body Weight vs. Dulaglutide across Baseline BMI Subgroups in SUSTAIN 7
Authors: VILJOEN ADIE , BLUHER MATTHIAS , CHOW FRANCIS C.C. , ROUX CAREL LE , ROSENSTOCK JULIO , LAUSVIG NANNA L. , YILDIRIM EMRE , LINGVAY ILDIKO 
Published: June 2018

Semaglutide, a new GLP-1 analog for the treatment of T2D, showed significant and clinically meaningful reductions in HbA1c and body weight (BW) across the SUSTAIN clinical trial program. SUSTAIN 7 compared semaglutide vs. dulaglutide (both once weekly) head-to-head in subjects with T2D both as add-on on metformin over 40 weeks. This exploratory analysis assessed treatment effect of semaglutide 0.5 mg vs. dulaglutide 0.75 mg and semaglutide 1.0 mg vs. dulaglutide 1.5 mg by baseline BMI subgroups (&lt;25, 25-&lt;30, 30-&lt;35, ≥35 kg/m2) on weight loss (WL). At week 40, mean BW (baseline 95.2 kg) was reduced across BMI subgroups: 3.6-5.5 kg vs. 0.9-3.4 kg with semaglutide 0.5 mg vs. dulaglutide 0.75 mg and 5.2-7.6 kg vs. 2.0-3.8 kg with semaglutide 1.0 mg vs. dulaglutide 1.5 mg (Figure). Higher baseline BMI generally led to greater treatment-induced WL. More subjects achieved ≥5% and ≥10% WL with semaglutide vs. dulaglutide in all subgroups. In the ≥35 kg/m2 subgroup, ≥10% WL was achieved by 14% of subjects with semaglutide 0.5 mg vs. 4% with dulaglutide 0.75 mg, and 25% with semaglutide 1.0 mg vs. 6% with dulaglutide 1.5 mg; 39% vs. 27% and 58% vs. 32% of subjects achieved ≥5% WL, respectively. AEs occurred at similar rates across BMI subgroups in all treatment arms.

In conclusion, BW reductions were greater with semaglutide vs. dulaglutide regardless of baseline BMI, consistent with findings in SUSTAIN 1-5 assessing semaglutide vs. comparators.

Disclosure

A. Viljoen: Research Support; Self; AstraZeneca. Speaker's Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Napp Pharmaceuticals, Ltd.. Research Support; Self; Novo Nordisk Inc.. Advisory Panel; Self; Eli Lilly and Company, Novo Nordisk Inc.. Consultant; Self; Sanofi-Aventis. Research Support; Self; Sanofi-Aventis. Speaker's Bureau; Self; AstraZeneca, Eli Lilly and Company. M. Bluher: Advisory Panel; Self; AstraZeneca. Speaker's Bureau; Self; Bayer AG. Advisory Panel; Self; Eli Lilly and Company. Speaker's Bureau; Self; Novartis AG, Novo Nordisk A/S, Sanofi-Aventis Deutschland GmbH, Amgen Inc., Boehringer Ingelheim GmbH. F.C.C. Chow: None. C. le Roux: Advisory Panel; Self; Novo Nordisk A/S, Johnson & Johnson Services, Inc.. Speaker's Bureau; Self; Boehringer Ingelheim GmbH. Advisory Panel; Self; GI Dynamics Inc.. Speaker's Bureau; Self; Orexigen Therapeutics, Inc.. Advisory Panel; Self; Herbalife International of America, Inc. J. Rosenstock: Advisory Panel; Self; Eli Lilly and Company. Consultant; Self; Eli Lilly and Company. Research Support; Self; Novo Nordisk Inc.. Consultant; Self; Novo Nordisk Inc.. Advisory Panel; Self; Sanofi. Consultant; Self; Sanofi. Advisory Panel; Self; Janssen Pharmaceuticals, Inc.. Consultant; Self; Janssen Pharmaceuticals, Inc.. Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Advisory Panel; Self; Intarcia Therapeutics, Inc.. Consultant; Self; Intarcia Therapeutics, Inc.. Research Support; Self; Merck & Co., Inc., Pfizer Inc., Sanofi, Novo Nordisk Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Intarcia Therapeutics, Inc., Genentech, Inc. N.L. Lausvig: Employee; Self; Novo Nordisk A/S. E. Yildirim: Employee; Self; Novo Nordisk A/S. I. Lingvay: Advisory Panel; Self; Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca, Intarcia Therapeutics, Inc., Sanofi-Aventis. Research Support; Self; Novo Nordisk A/S, Merck Sharp & Dohme Corp., Pfizer Inc., GI Dynamics Inc., Novartis AG. Other Relationship; Self; Sanofi, AstraZeneca, Boehringer Ingelheim GmbH, Novo Nordisk A/S.